Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme Cancels Phosphate Binder Development | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Genzyme Cancels Phosphate Binder Development

Genzyme Corp. reported results of a Phase II/III study of its advanced phosphate binder (APB).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme Corp. reported results of a Phase II/III study of its advanced phosphate binder (APB). Although the trial met its primary endpoint, which was to show that the APB lowered phosphate levels compared to placebo, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela.

As a result, the company is discontinuing further development of the drug. The company was looking to develop a product with higher potency that would more effectively bind phosphate, while maintaining all the benefits of Renvela.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters